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Abstract
“Readiness cohorts” are an innovation in clinical trial design to tackle the
scarcity of time and people in drug studies. This has emerged in response to
the challenges of recruiting the “right” research participants at the “right
time” in the context of precision medicine. In this paper, we consider how
the achievement of “readiness” aligns temporalities, biologies, and market
processes of pharmaceutical innovation: how the promise of “willing bod-
ies” in research emerges in relation to intertwined economic and biological
time imperatives. Drawing on long-term engagement with the field of
Alzheimer’s disease prevention and interviews with researchers from
academia and the pharmaceutical industry, we describe the discursive
construction and practical arrangement of readiness. This paper con-
tributes to understandings of temporal specificity, or “timing,” within
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prevention research and casts critical light on the way this specificity—the
threshold for “trial readiness”—relates to an opaque and highly speculative
drug development pipeline. Extending the study of biomedical potential, as
that which holds promise but may not yet exist, we consider how absences
operate in adaptive trials. By highlighting these absences (“ready for
what?”), we outline an opportunity for socio-ethical research to intervene
in the speculative gaps of drug development.
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Introduction
Time is a scarce resource in the world of clinical trials, in which timelines for
recruiting and conducting trials present significant challenges (Montgomery
2017). In addition, the timing of disease progression has an increased sig-
nificance in the growing number of trials focusing on preventative therapies,
which rely on early detection of biomarkers (Kerr et al. 2019; Swallow 2020)
as “silent” indicators of risk (Dumit 2012a). Such pressures have contributed
to the emergence of new clinical trial practices, including “adaptive” methods
(Montgomery 2017) and practices of “recruitmentology” that promise
increased efficiency in clinical trials and the expansion of study populations
(Fisher 2007; Epstein 2008). However, as Montgomery and Pool (2017, 2)
point out, the “experimental publics” of clinical trials are partial, emergent,
and temporally contingent; they “enact and are enacted in relation to the
research practices they are presumed to pre-exist”.
In this paper, we examine challenges of time and recruitment in the
context of the move to precision or stratified medicine, focusing on
“readiness”: the state of being ready to participate in, or launch, a pharma-
ceutical drug trial. We explore the dynamic configuration of experimental
publics from the perspective of pharmaceutical innovation and its intersection
with longitudinal research (Mitchell and Waldby 2009). We consider how the
creation and coordination of readiness involves aligning specific time points
along biological trajectories and market processes of pharmaceutical innova-
tion. In doing so, we show how the promise of “willing bodies” in research
emerges in relation to intertwined economic and biological time imperatives
in drug development: the pursuit of a future in which disease is caught “early”
and progression stopped “quickly.”
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Our paper draws on a five-year engagement with the case and a series of
expert interviews with researchers from academia and the pharmaceutical
industry involved in preparing a phase II clinical trial. Our purpose is to
demonstrate how readiness is defined and enacted: what or who determines
change through time, and where are the thresholds of readiness in biological
and drug development trajectories? By examining the operationalization
and practical arrangements of readiness in clinical trials from the perspec-
tive of experts in this field, we seek to understand the concept of readiness
as both an analytic and an object of study (Taussig, Hoeyer, and Helmreich
2013). This paper thus contributes to our understanding of temporal speci-
ficity, or “timing,” within prevention research, particularly in the dementia
field where time is crucial to both the conceptualization of disease trajec-
tories and the organization of pharmaceutical drug trials. It also casts a
critical light on the way this temporal specificity—the threshold for “trial
readiness”—emerges in relation to an opaque and highly speculative drug
development pipeline.
In the following sections, we locate readiness within wider thinking
about temporality, biomedicine, and techno-scientific progress before going
on to introduce the Alzheimer’s disease research context, our specific case,
and our methodology. The empirical material then explores the discursive
construction and practices of producing readiness: first, as a state within the
brains and minds of study participants, who thus become “trial-ready”
subjects; then, as a broader sociotechnical arrangement including (the
potential of) pharmaceutical drugs; and finally, as an achievement of spec-
ulative, anticipatory practices between the drug development pipeline and
on-the-ground clinical research. In concluding, we consider how socio-
ethical interventions can open up the “speculative gaps” we identify to
make space for other (neglected) actors, tools, and stories within the field
of Alzheimer’s research.
Conceptualizing Readiness
Moving away from narratives of naturalized trajectories of decline and
intervention that dominate Alzheimer’s disease research, we are interested
in the temporal organization of bodies, brains, technologies, and drugs. In
our research, readiness pertains to a particular point in the aging process
within potential trial participants, but it also speaks more broadly to the
sociotechnical organization of time in drug development and neurological
research. Following trends in trial research, the European Prevention of
Alzheimer’s Dementia (EPAD) study operates from a future-oriented
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position, shoring up disease modeling and other biostatistical methods to
anticipate the need to adapt the design or let drugs “fail quicker” (Mon-
tgomery 2017). Given the aforementioned conditions of time-sensitive
interventions and economic time pressures, the logics of a readiness cohort
in Alzheimer’s disease research are about organizing and optimizing the
temporalities of both the disease and drug development. These logics bring
readiness into contact (and contrast) with vocabularies of future orientation
in techno-scientific contexts such as notions of timing (Brown 2000), antic-
ipation (Adams, Murphy, and Clarke 2009), potentiality (Taussig, Hoeyer,
and Helmreich 2013), and speculation (Bryant and Knight 2019; Wilkie,
Savransky, and Rosengarten 2017).
In describing this organization and optimization of temporalities, we
attend to what is present, what is absent, and what is “not yet” when it
comes to disease trajectories and drug development. Dumit’s (2012b) work
on thresholds for “at-risk states” is helpful for understanding readiness as a
function of disease trajectories. His description of health and illness on
a continuum, with a decided-upon line between them, is illuminating in a
field (such as Alzheimer’s disease) where these lines are often redefined; in
Dumit’s words, “the line is determined not by overt pathology but by
clinical trials” (p. 105, our emphasis). As we go on to describe in more
detail, this threshold line has been shifted from the clinical stage of demen-
tia (symptomatic) to the preclinical period (“no symptoms yet”). Already it
is becoming clear that in setting the threshold for trial readiness in Alzhei-
mer’s disease research, timing is everything.
This story contains another “not yet,” which is crucial to conceptualizing
readiness. At the time we carried out the research (and as we write), there
was no existing treatment to halt or reverse the effects of dementia. More-
over, the specific intervention was yet to be secured within the project,
making the intervention drug a “manifest absence” in this particular trial
platform (Law 2004, 83). However, given that such absences are “always
potentially contestable” (Law 2004, 83), we explore how objects and people
work together or in tension to bring possible futures into the present
(Wilkie, Savransky, and Rosengarten 2017). Here, we draw on Bryant and
Knight’s (2019) discussion of speculation as a future-oriented engagement
with absence or “gaps.” For example, we think with the case study in which
investments in speculative futures transform “no oil” into public rhetoric of
“no oil yet” (Weszkalnys 2015, in Bryant and Knight 2019, 98). In our
context, how might the future-oriented logics of readiness transform the
current predicament of “no drugs” into a rhetoric of “no drugs yet?”
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In a similar vein, the concept of potential opens up analyses of that which
holds promise but may not yet exist (Gibbon 2013; Taussig, Hoeyer, and
Helmreich 2013)—a logic that may explain hopeful attitudes toward drugs
that keep being produced and tested but do not yet exist as viable treat-
ments. It is here, in the work of narrating scientific progress, that we see the
“practical orchestration of present problems and future solutions” described
by Brown (2000, 89) in his “breakthrough motif.” Of particular interest to
our conceptualization of readiness as comprising temporal specificity and
potential is Brown’s use of the rhetorical notion of “Kairotic moments”
(Brown 2000, 89), which are constructed as the right time for action (both
by making predictions about the future in an anticipatory mode and by
narrating events in retrospect (Brown and Michael 2003). If readiness marks
the right time for pharmaceutical intervention, what makes this moment
“right?” And why is this interesting both empirically and conceptually?
Following Taussig, Hoeyer, and Helmreich’s (2013) approach to an
“anthropology of potentiality,” we explore how readiness operates as both
an object of study and an analytic.
“Reengineering” Alzheimer’s Disease Prevention
Our paper concentrates on pharmaceutical research in the context of Alz-
heimer’s disease. Despite intensive efforts, two decades of clinical trials in
Alzheimer’s disease have yet to identify a drug that is able to change the
course of the disease. In response, there has been what researchers describe
as a “paradigm shift,” from curing symptomatic disease to preventing the
emergence of symptoms, and concurrently, from a model of disease based
on clinical and behavioral symptoms to one that privileges biological signs
and changes in these (Lock 2013; Milne and Latimer 2019).
In a field so troubled by repeated failure, the cultivation of future promise
in Alzheimer’s research has involved reinforcing the biological framing of
disease in the hope that this might improve the accuracy of prediction
(Swallow 2020). Where research and trials previously targeted people who
had the disease in the hope that they could eventually mitigate or reverse the
effects of the disease, the emerging “preventative assemblage” (Niewöhner
et al. 2011) of Alzheimer’s disease now seeks to treat people who do not yet
have the disease but are “at risk” (Lock 2011; Leibing 2014). The current
consensus in the neuroscience and clinical trials community is that the main
problem with previous pharmaceutical therapies is that they have not caught
the disease early enough or in subtle enough ways (Molinuevo et al. 2016).
To date, this approach has met with little success; the value of tracking and
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targeting biomarkers (understood as biological proxies of “predisease” states)
remains hotly contested (Frisoni and Visser 2015). Nevertheless, the
“anticipatory politics” (Jae 2018) of early detection and pharmaceutical pre-
vention is sufficient to mobilize a whole field of disease-modifying clinical
trials for Alzheimer’s. Such trials necessarily involve people who do not
fulfill symptomatic criteria for disease and who may consequently neither
be seeking treatment nor accessing healthcare (Molinuevo et al. 2016).
The changing goals of clinical trial research have been accompanied by a
shift in approach. Conventional models of clinical trials have been
described by leading figures in Alzheimer’s disease research as “broken”
(Cummings et al. 2016). New approaches thus involve not only a funda-
mental “reengineering” of the nature of the disease being targeted (Cum-
mings et al. 2016) but also new forms of measurement, revised regulatory
guidance related to the goals and outcomes of trials, new collaborations
between public and private sectors, and innovative trial designs that aim to
speed the trial process and deliver results more quickly (Aisen et al. 2016;
European Medicines Agency 2014). The move toward involving
“minimally affected optimally selected study participants” (Jimenez-
Maggiora et al. 2020, 226) aims to bring temporal specificity and, therefore
efficiency, to the costly and time-consuming process of selecting, screening,
and recruiting potential participants.
At the core of these interconnected shifts is the alignment of a
diverse group of socio-technical actors concerned with identifying the
appropriate moment in the temporal progression of the disease for
techno-scientific intervention. The model, as elaborated by influential
clinical trialists in Alzheimer’s disease, involves “accelerating” the clin-
ical trial process (Aisen et al. 2016); effective “subject selection”
(Vellas et al. 2011) and “stratification” (Carrillo et al. 2013) of the
research population; and “large-scale co-operation” among the actors
involved in funding, conducting, and regulating Alzheimer’s disease
drug research (Aisen 2009).
The EPAD Study
We attend to a particular manifestation of these temporal concerns and
practical realignments, within a large-scale project: the EPAD study. EPAD
is one of a number of public–private collaborations in Alzheimer’s disease
research funded through the European Innovative Medicines Initiative
(IMI). It was established as a result of the IMI’s “European Platform for
Proof of Concept for Prevention in Alzheimer’s Disease” (EPOC-AD) call.
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IMI topic areas are determined in line with recommendations from industry
to address “bottlenecks” in drug development and are intended to create the
potential for precompetitive collaboration between large and small biotech
and pharmaceutical companies (Goldman 2011), although as IMI leaders
acknowledge, the boundaries of what constitutes “precompetitive” are nei-
ther clear nor static (Goldman 2011; Laverty and Meulien 2019).
The EPOC-AD call described the IMI’s intention to invest €25 million—
with an equivalent contribution from EFPIA—to create a “precompetitive
space to enable collaboration for optimizing patient selection, clinical trials
methodologies, and candidate therapies” (Innovative Medicines Initiative
2013, 19). The call describes how this would “de-risk the enterprise” of
Alzheimer’s disease drug development (Innovative Medicines Initiative
2013, 29), by creating a platform that would not benefit any single program
of drug development but would be available for simultaneous use by oth-
erwise competing companies. Initial industry involvement in the project
included commitments from a number of large and smaller pharmaceutical
companies including Janssen, Eisai, Roche, AbbVie, AC-IMMUNE,
Amgen, Astellas, BIOGEN IDEC, Boehringer Ingelheim, Lundbeck, Pfi-
zer, and UCB (Innovative Medicines Initiative 2013, 32). These companies
were involved to differing extents in the development of the project and,
indeed, in Alzheimer’s drug development overall (Cummings et al. 2017).
However, by participating in the IMI call, each could expect to be able to
shape and use the potential EPAD platform.
The value to industry of the EPOC-AD/EPAD approach was described in
a mid-2013 workshop held by the New York Academy of Sciences. Michael
Ropacki of Janssen Alzheimer Immunotherapy set out a “Registry Recy-
cling Model,” in which individuals would be enrolled in an observational
cohort study, from which
Clinical studies can then draw . . . to create a population of well-characterized
subjects, shortening the enrolment period and increasing both the efficiency
and efficacy of trials. (Bain 2013, our emphasis)
At an Organisation for Economic Co-operation and Development
(OECD) workshop held shortly after the EPOC-AD call, Luc Truyen (also
of Janssen) described how the EPAD program would create “a standing trial
ready platform combining direct access to well characterized subjects with
sites certified and ready to engage trial participants” (OECD 2015, 19).
Readiness was thus central to the conceptualization and establishment of the
EPAD program and continues to inform the development of initiatives such
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as the Trial Ready Cohort for the Prevention of Alzheimer’s Disease, which
champions the “minimally affected optimally selected” recruitment approach
referenced above (Jimenez-Maggiora et al. 2020). Thus, EPAD was one of
several initiatives seeking to minimize the investment of time and money in
recruiting eligible participants and to “beat the (biological) clock” when it
comes to intervening in disease progression. Here, the stage is set for the
launch of the readiness cohort by members of a core group of actors who were
defining the terms and setting up the conditions for this cohort to become a
population of potential trial participants.
Given its centrality to the reimagining of Alzheimer’s disease trials
occurring through these initiatives, we propose that the construction of
readiness—the right moment for the right individual to respond optimally
to a given drug—warrants close empirical investigation. Our discussion
draws on our work in social science and ethics embedded within the EPAD
study. This work on “ethical, legal and social implications” (ELSI) con-
centrates on new approaches to clinical trial recruitment and the move to
focus on asymptomatic or mildly symptomatic populations in Alzheimer’s
disease research (Milne et al. 2017). Enacting our role as (post-)ELSI
researchers (Balmer et al. 2015), we carried out this study as observers
of, and researchers within, EPAD. We draw on continuous involvement
in the study since its inception, and eleven expert interviews with scientific
researchers (from research assistants to the study’s executive committee)
and pharmaceutical industry partners, exploring perspectives on what readi-
ness “is” and how it was being “done” throughout the EPAD infrastructure.
These data were generated at a crucial moment in the project, in which
actors were preparing to launch a phase II clinical trial after several years of
observational research on Alzheimer’s disease trajectories. We begin by
exploring how readiness was defined, before drawing out how specific
thresholds for readiness emerged in practice and the speculative work
involved in managing the drug development pipeline.
Part I: Readying Participants
“Readiness is . . . ” a dual definition
So, I would define it as people who are ready to go into interventional studies;
people who are both ready from a biomarker point of view, so they have the
biomarkers of Alzheimer’s disease, but also people who are ready . . . I guess
mentally? (Trial coordinator)
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In interviews between meeting sessions on the science and practicalities
of the future trial, one of the first questions we would ask was “what is
‘readiness’ in the context of the ‘readiness cohort?’” The starting point
of responses coalesced around two aspects of readiness: a (bio)technical
aspect and a psychological or “mental” one, both located within the
individual. The (bio)technical aspect (hereafter “technical” readiness)
was, as the trial coordinator above put it, about being ready to partic-
ipate in a drug trial “from a biomarker point of view.” This corre-
sponded to the inclusion and exclusion criteria of the study and, as
another trial coordinator called it, “that aspect of ticking the boxes of
a trial.” The psychological aspect, on the other hand, was about (poten-
tial) participants’ willingness, consent, and engagement—emotional and
intellectual—with the idea of being in a pharmaceutical drug trial.
According to these accounts, individual subjects became ready in two
ways—in brains and in minds—as the study progressed toward launch-
ing the trial. We take this dual definition as a point of departure for
thinking about how readiness is understood and operationalized
throughout the study and the future trial.
Although psychological readiness was considered in terms of individual
volition and cognition, this state of mind (and its maintenance) had impli-
cations throughout the study. Psychological readiness is crucial, not just
because of the rights and well-being of participants but because of what is at
stake if participants drop out. There is no threshold at which psychological
readiness has been definitively achieved; it is a state that has to be sustained
and maintained. As a US-based industry representative stressed, “maybe
even the worst thing that can happen is you actually enroll somebody and
then they drop out.” He went on:
Because you’ve invested the quarter of a million dollars of time and money of
all the professionals and the sponsor to get that person qualified to be in that
trial. And then because they weren’t emotionally committed to it, or their
caregivers weren’t, they drop out.
His comments make clear the value of “readying” work through the
clinical trials enterprise. Trialists took seriously the fragility of people’s
motivations to participate, be it altruism or hopes for access to successful
disease-modifying treatment (or, in the words of the US industry represen-
tative, “love of self, love of family, love of country”). The possibility of
participants dropping out hung heavily over everyone who had invested in
the trial—financially, emotionally, and scientifically.
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“That’s why we do epad—to understand the timing”
Closely related to the within-person aspect of readiness was the within-
brain aspect. In contrast to psychological readiness, there were quantitative
measurements and thresholds for the technical, “tick-box” aspect of readi-
ness. Thresholds for technical readiness were based on two important mea-
sures: first, levels of the beta-amyloid in the brain, the protein most
commonly implicated in the etiology of Alzheimer’s disease and the target
of most disease-modifying clinical trials to date; and second, the clinical
dementia rating score, a wide-ranging assessment of cognitive function.
At the outset of a trial, the way thresholds function is in theory simple:
participants must meet the first threshold (showing that enough beta-
amyloid has built up in the brain) and they must not exceed the second
(showing that they do not have a dementia rating score of 1.0, which would
mean they could be clinically diagnosed with dementia). These thresholds
are important when planning a prevention drug trial because everything
depends on understanding the nature and pace of change, and in so doing,
framing the point in a disease process where a compound might most
effectively “act.” Indeed, one trial coordinator summed up the rationale for
the project in terms of these temporal thresholds: “That’s why we do
EPAD—to understand the timing.”
When it came to understanding the “timing” of Alzheimer’s disease,
there was a strong focus on the very early stages of the disease. But while
some people talked of these early stages being the disease, others described
them as more of a precursor: such as the industry partner who described
them as “participants who have signals, with a higher risk.” The technical
thresholds set centrally by the project executive committee thus became
pivotal to resolving these conceptual ambiguities and defining readiness.
These technical readiness thresholds indicated an optimal moment for trial
participation, when signs of pathology were considered to be most amen-
able to pharmaceutical intervention.
While psychological readiness was presented as socially produced and
changeable, this technical aspect was “black-boxed” (Latour 1987) as a
biological process within the brains of participants. In theory, reaching
these fixed thresholds was contingent only on the timings and processes
of the aging brain. However, in the following sections, we encounter aspects
of readiness that were contingent on processes, people, and materials
beyond the individual: a more distributed conceptualization of readiness
than the initial descriptions suggested. As we go on to demonstrate, see-
mingly fixed thresholds were subject to alterations that reflected the
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processes and politics of drug development. We focus on one particular
threshold shift and contextualize it among the moving parts of the study.
Part II: Sociotechnical Coordination of Readiness
In opening up the “black box” of readiness thresholds, we found that con-
siderable organization went into producing technical as well as psycholo-
gical readiness. What is more, we saw ongoing adjustments to the study that
shifted the threshold for readiness and therefore the status (“ready” or “not
ready”) of many cohort participants.
As we have described above, technical thresholds for readiness were in
theory about having crossed the threshold for one key biomarker, beta-
amyloid, and having not yet crossed the threshold for a clinical diagnosis
for dementia. As a participant, you could, by this logic, only become “not
ready” when you became clinically diagnosable with dementia. Having a
diagnosis of dementia meant you would have passed the preclinical phase; it
would be assumed there was no stopping the disease progressing, and
therefore you would no longer meet the inclusion criteria for the trial.
In practice, however, there was another crucial way in which many people
became “not ready” and therefore ineligible for the trial. In 2015, in the initial
phases of the EPAD study, a core expectation was that future interventions
would focus on people who had no symptoms of cognitive impairment at all
but who exceeded a threshold for amyloid levels (referred to as “amyloid
positive”). This reflected contemporaneous expectations about drug develop-
ment, captured in the new guidance from regulators and the growing interest
in studies among people without symptoms (European Medicines Agency
2014; Molinuevo et al. 2016). However, about three months before our inter-
views, this focus on completely symptomless or “silent” Alzheimer’s disease
changed, with consequences for all the other “readying” work that we have
been describing. A trial coordinator explained this when asked about how
recruitment was going in the context of these changes:
Interviewee (I): of course, now we have a different kind of trial lined up,
and that has changed the approach in EPAD dramati-
cally. The idea that we had in our minds since the
beginning was that we were focusing more on the pre-
clinical phase of Alzheimer’s. And that’s what we’ve
had in mind with recruiting as well. But now of course
we’ve shifted our attention to MCI (Mild Cognitive
Impairment) patients . . . . So that makes a huge differ-
ence for how to recruit and who to recruit.
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Interviewer (NB): At what moment did you feel “OK that really shifted?”
I: Yeah, that’s a good question. (The PI) sent out an email
last couple of months ago, that was the official
announcement that says, “we’re really focusing on our
efforts on MCI recruitment now,” . . . Before that, I
think it was communicated more between the lines.
NB: OK, and how did the official announcement change
things?
I: It’s all going to change now . . . before the message was:
“OK, we’re behind on recruitment, recruit as many as
you can,” and our programs were let loose . . . but now
of course those people are—they’re less valuable in
terms of this specific trial.
NB: So, it’s like the terms of the readiness have shifted?
I: Yeah, that’s a good way of phrasing it.
This conversation charted the unfolding of an event that—confusingly—
caused many people to become “not ready,” without developing a clinical
diagnosis of dementia. The initial focus on entirely preclinical (asympto-
matic) Alzheimer’s disease had given way to one that incorporated mild
symptoms known as the prodromal phase of the disease. So, this was not
about participants becoming ineligible for a trial because they had devel-
oped clinically diagnosable dementia. In fact, the participants who became
“less ready” were those who were more cognitively healthy and who did not
(yet) have signs of MCI. The reason for them becoming “not ready” was
that the terms of readiness had changed. The threshold had moved further
along the scale of cognitive decline to include the “prodromal” condition of
MCI. The threshold had been destabilized, but it was clearly contingent on
something else, aside from biology, psychology, or general scientific
consensus.
Readiness is . . . in the drug?
If you talk about trial readiness for if a person is ready—well that depends on
the compound (Trial coordinator)
What was this “something else” that readiness was contingent on, beyond
the biology and psychology of the participants in the readiness cohort? And
what does this tell us about the values and materials that shaped and ani-
mated the project? The answer to the first part of this question emerged
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throughout many of our interviews, usually soon after it became clear that
criteria for becoming ready were more fluid in practice than in theory.
Whether or not people were ready for this trial, we were told, was depen-
dent on what kind of trial it was going to be and, specifically, on which
compound the trial would be testing. As one industry partner involved in
the operations of the study described, this meant that readiness fluctuates
over time, as different drug owners come in with potential “interventions”
for the trial:
Yes, and indeed that point will differ over time again . . . readiness will look
different in a year from now, in two years from now, because two interven-
tions might come on board. A third intervention might come on board with all
different expectations and eligibility criteria so then the readiness might look
completely different. For instance, if the first PoC (Proof of Concept trial)
will be let’s say a prodromal subject, then you’re kind of losing the readiness
of the preclinical subjects because there is no PoC trial for them . . . . So, you
see it kind of fluctuates.
This interview fragment describes exactly what the trial coordinator
above was talking about, but this time, from an industry perspective. We
hear about the moving parts of the trial responding to the kind of drug being
added into the protocol. Earlier in the interview, she described the protocol
as the “backbone” to the study, from which nothing could be removed but to
which new trials could be added. It was one of these trials whose potential
arrival set in motion the shift in the “terms of readiness,” which made all of
the asymptomatic subjects (with amyloid biomarkers) lose their status of
being trial-ready.
The drug as actor: power and potentiality
Several people we spoke to across industry and academia echoed this idea
of “flexibility,” “fluctuation,” or “fluency” in the operational definitions of
readiness. Despite all the work that went into readying participants, to make
sure they were willing to go into a drug trial and aware of the potential
promise of that trial, there was always a chance that the drug itself would
override this and make those very same participants ineligible for the trial
(counterintuitively making them “become not ready”).
Here, the creation of a readiness infrastructure oriented toward potential
future trials disrupts conventional drug-development processes, in which
trial development follows, rather than precedes, the existence of a potential
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therapeutic agent. As a “precompetitive” collaboration aimed at establish-
ing an infrastructure for trials, EPAD was at the mercy of the unfolding of
“competitive” company development pathways. This contributed to con-
cern about the power of the compound to technically “de-ready” partici-
pants who were psychologically “ready” to move into the trial. In such a
situation, there was little that could be done to alter the “demands” of the
drug.
How the drug acted on the trial platform and, in particular, the opera-
tionalization of readiness was distinctly future-oriented throughout the proj-
ect. Unlike many of the more complex or subtle potential outcomes of
EPAD, such as increased knowledge of how and why Alzheimer’s disease
develops in certain ways, the powerful potential of the drug was, quite
simply, that it might work:
People want to be part of this family, want to succeed, want to see eventu-
ally—does it work? I’m sure the drug companies want to see it work-
ing . . . we’re all so disappointed with the failure of aducanumab1 that we’re
going, please let this work.
These were the words of a recruitment team member, who had spent her
career working with people with dementia and held huge hope for finding a
cure. Other respondents were also concerned with the potential of the drug
working but their accounts indicated varying degrees of influence over
whether it would act in the desired way. Some were in a better position
than others to manipulate the moving parts of the study to ensure the drug
had the best possible chance of working and—more specifically—on which
particular types of participants it might work best. For example, a biosta-
tistician talked about finding the right (future) patient on which to make the
drug work. When discussing the use of MCI as a proxy for trial readiness, he
lamented the fact that trialists often tried to find these participants without
more sophisticated predictive data to tell them whether or not these patients
were “right.” He insisted that through disease modeling, they could deter-
mine whether participants were on the “Alzheimer’s pathway,” whether
they were “likely to progress,” and whether they were “the right patient.”
For him, and others invested in the future trial, the potential of the drug was
something to be predicted, modeled against data, and then cultivated
through the selection of people most likely to respond to the compound
available at any given time.
A story about the development of a clinical trial platform characterized
by “flexibility,” “fluctuation,” or “fluency” bears little resemblance to the
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broken “machine” in need of “reengineering” within the clinical trials lit-
erature (Cummings et al. 2016). Even more striking is the interdependency
of different elements, namely, the way in which eligibility criteria, biolo-
gical thresholds, and readiness itself both create the conditions for and
respond to particular drugs. These drugs, therefore, came to be a driving
force of the study, even as they remained an unconfirmed potential within
the “pipeline” of potential pharmaceutical owners. In the final part of our
findings, we attend to the temporal, future-oriented, and ultimately spec-
ulative nature of this driving force.
Part III: “Ready for What?” Animating Absence,
Choreographing the Future
So, we had to give a message that “there are going to be trials started some-
where in the course of EPAD, and the goal of that trial is to try to influence
the course of Alzheimer’s disease, but we’re not really sure what it’s going to
be yet, and we’re also not sure whether you will be eligible for
it” . . . participants wanted to be ready, but ready for what? And at what time?
(Trial coordinator)
We have hitherto described how thresholds of readiness were contingent on
and responsive to the particular drug that was “in the pipeline” at any one
time. In this final part, we follow the “moving parts” of the clinical trial—
research—drug development nexus to the speculative promise of the can-
didate drug. The quote above illustrates the glaring unknowns surrounding
the drug and its introduction into the trial: “ready, but ready for what?”
Highlighting this speculative aspect of the trial, we consider how invisibil-
ities and absences in the drug development pipeline operate in relation to
the more present aspects of the study, and how we as researchers might
work with speculation as a mode of engagement with the future of dementia
prevention research.
The opacity of the drug development pipeline
The inclusion and exclusion criteria for the readiness cohort and the pro-
tocol for the connected proof of concept trial had been clearly defined at this
point of the study. However, it remained unclear what these had changed for
and what potential future treatment the drug trial was offering. One
researcher described the situation as being “all a bit cloak and dagger at
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the moment,” given that the specific drug to be tested was yet to be
revealed. Most people involved in coordinating the study and collecting
data knew on what and in whom the drug was likely to act (i.e., on the
protein “tau,” in “prodromal” participants), but almost no one knew
anything about the drug itself or to whom it belonged. The reason for
this opacity was the uncertainty and precarity of the process of securing
the drug with the intervention owner (the pharmaceutical company),
which the future of the trial depended on. In fact, most of the study’s
leadership described the intervention not as one solid intervention pack-
age, but as a number of possible interventions “in the pipeline,” with
one intervention holding most promise for the future trial at any given
time.
This uncertainty emerged from the project’s position at one intersection
of “precompetitive” and “competitive” space in drug development. Predi-
cated on the creation of a platform through precompetitive collaboration,
the ultimate operation of the platform depended on engagement with the
“competitive” spaces of drug development. This was reflected in the dif-
ference between the transparent development of the platform and the opa-
city of the trial. Only a small and select number of people who had entered
into nondisclosure agreements with potentially interested companies could
“see into” the drug pipeline. Its contents had to remain secret until a final
contract had been secured with the owner of the drug, with the wider
consortium informed only that discussions were ongoing with a company
about a drug at a particular stage and with a particular mode of action (e.g.,
an anti-amyloid drug currently at phase I). Although the project was a
public–private partnership, the industry partners who were already involved
were not necessarily those who would use the platform, with other, external
intervention owners also able to buy in and start testing their compounds.
This was delicate—a process one member of the study’s executive com-
mittee described as “the intervention owner giving away their baby,” going
on to emphasize what a “valuable asset” a promising compound is to a
company. And so, while the readiness of participant bodies and brains was
constantly being measured and made visible, the (non)readiness of the drug
was being kept largely invisible.
The drug as absence: An “ontology of withdrawal”
While the drug was described in some conversations as being invisible, in
others, it was talked about as being manifestly absent (Law 2004):
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Oh [the readiness cohort] is a great idea! But we need a drug now. Today. We
need a drug two years ago.
This came from an industry partner, whose involvement in a number of
other clinical trials made her skeptical about whether the trial platform was
“ready” to enter into the next phase of drug testing. As described above, the
commitment of the IMI and its industry partners was to create a shared
framework for potentially competing actors to conduct simultaneous trials.
Understandably, therefore, this partner was concerned about the lack of a
drug itself at this crucial point in the study. After all the discussion about a
particular drug determining the readiness of participants, this drug became
evanescent when it came to operationalizing it in the trial itself. Even more
curiously, many of our interviewees and participants in the meeting
accepted this absence and maintained that the drug trial was ready to go
ahead. In contrast, for another senior data scientist involved in the trial
platform:
. . . the first goal of EPAD is to deliver a clinical trial: The proof-of-concept
trial. So, is EPAD ready for that? I think, absolutely.
These answers were not the only diametrically opposed responses to our
question about the “readiness” of the trial platform itself, there was little
agreement on this among our interviewees. After so much protocol adjust-
ment to achieve agreement about participant readiness, this disagreement
about the implication of the absent drug was striking.
Unlike the modeled trajectory of cognitive and biological decline that
provides its basic logic, the trajectory of drug development itself emerged
as unpredictable and nonlinear. In narratives about the readiness of trial
platform, the potentiality of the drug was less about an innate potential of
the compound and more about the potential of what might be, but is not yet
there. This is the “complex work” of potentiality: “to imagine or talk about
potential is to imagine or talk about that which does not (yet and may never)
exist” (Taussig, Hoeyer, and Helmreich 2013, S4). Indeed, at the time of our
research, the absence of the drug was what held the potential to do what
previous drug trials had repeatedly failed to do: work on earlier-than-ever
stages of the disease trajectory to stop cognitive decline.
This future orientation speaks also to the notion of speculation, the
practice of casting into an unknown future from a known present. The
opaque “cloak and dagger” of the drug pipeline animates Bryant and
Knight’s (2019, 83) conjecture that speculation is where the “weirdness
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of the world” and “our inability to pin it down” leads to imaginative knowl-
edge practices. Our attempts to follow the drug in our interviews, only to
find it vanishing from view, echo what Bryant and Knight call the “ontology
of withdrawal”: of things disappearing or not making themselves known as
we inhabit the speculative gap.
Working in the speculative gap (or, the intervention’s new clothes)
In this paper, we have opened up the sociotechnical “black box” of the
readiness cohort, attending to what was present, what was absent, and what
was “not yet” in this particular case study. Crucial to this has been exposing
how the drug operated as a “not yet”—something which has taken on
renewed meaning as we reflect upon the trajectory of the trial platform now
that the project has drawn to a close. In fact, the intervention never arrived:
no trial was launched, and no drug was tested. The drug was (and remains) a
speculative, anticipatory entity, but no less powerful for it. The speculative
promise of the drug could not be taken away, because, on the one hand, so
much depended on it, and on the other, it did not (yet) exist. As Gibbon
(2013) has observed in the field of cancer genetics, science does not hold
innate potential but rather is imbued with it via various local articulations of
knowledge and technology. We can describe the drug as a powerful but
ambiguous placeholder in this study context: a placeholder around which
progress in drug development and testing are able to “happen” in various
ways in response to changing articulations of knowledge and technology.
Where does this leave our concept of readiness, dependent as it is on this
unreliable object?
Readiness, as an analytic as well as the condition we have been describ-
ing empirically, is characterized by its workability—its contingency on
moving parts and changing thresholds in a scientific project being put into
practice. It remains highly pragmatic, as well as fluid, in the context of the
trial platform. Its parameters and thresholds respond to the changing avail-
ability of potential drugs as well as the changing definitions of potential
(preclinical or prodromal) Alzheimer’s disease. Here, we are reminded of
Clarke and Fujimura’s “Right Tools for the Job” in which all these compo-
nents (tools, jobs, and “rightness”) are situational and contingent; and how
specifically, “designations of the ‘rightness’ of timing . . . is circumstantial”
(Clark and Fujimura 1992, 5).
The construction and maintenance of a readiness cohort appeared to be
full of linear movement toward disease modification or cure, seeking to stay
“one step ahead” of the disease trajectory itself. But what we learn from the
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operationalization of readiness is that trajectories of disease development
and pharmaceutical drug development are meticulously coordinated in a
forward-moving path, with the setting of readiness-thresholds being a key
part of this coordination. Attending to this tells us that the linearity of the
“readiness” story is constructed rather than natural (a now well-rehearsed
line of argument in Science and Technology Studies [STS]), but it also
highlights how specific threshold-setting is both defined by drug develop-
ment imperatives and what makes drug development work. Making drug
development work, in turn, makes a definition of Alzheimer’s disease as a
linear progression work. This observation speaks to other ethnographic
accounts of clinical trials and how their “therapeutic regimes” shape the
diseases that are their research objects (Cambrosio, Keating, and Nelson
2014). Readiness remains temporally defined and bound to the bodily and
cognitive change associated with dementia, but its specificity is shaped by
many other dynamic forces: material, political, financial, and scientific.
The need for temporal specificity is tightly bound to the story of
“reengineering” Alzheimer’s research, which we outlined in the introduc-
tion. The public–private partnership was deeply invested in developing
drugs that showed an effect on cognitive decline, even as the focus shifted
to earlier, less detectable stages of the disease. The promise of such partner-
ships is to enable companies to collaborate with each other and with public-
sector partners in a “precompetitive” way that “de-risks” pharma research
(Laverty and Meulien 2019). However, the process of establishing readiness
brings to the fore the balancing act involved in such efforts, between a
clinico-scientific logic of “earlier the better,” a commercial imperative not
to test drugs “so early” that effects would not be captured on regulator-
approved measures, and a funding and regulatory framework that attempts
to create a space for collaboration within a competitive industry. The self-
described “neutrality” of this collaborative platform (Laverty and Meulien
2019) was not about being intrinsically disinterested (financially or scien-
tifically), but rather the balance this act sought to achieve.
Conclusions
In this paper, we have followed our expert interlocutors’ definitions and
enactments of the temporal state of readiness. We have analyzed the thresh-
old for becoming trial-ready in terms of its temporal specificity: the right
moment for the right individual to respond optimally to a given drug. We
argue that this specific threshold is not only determined by the biologies and
psychologies of individual cohort participants, it is also a more distributed
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achievement, involving other actors and materials such as intervention
owners and the trial infrastructure itself. This makes space for a sociopoli-
tical analysis of “the timing” of drug treatments and trials in Alzheimer’s
disease and more broadly. Pushing this argument further, our empirical
material shows how readiness is also contingent on things that are absent,
or “not yet,” such as the drug yet to be tested within the trial platform.
Our approach shines a light on absent entities that nevertheless hold
power and potential; something we suggest opens up possibilities for a
speculative ethics in this field (Puig de La Bellacasa 2017). In this way,
we have exposed how thresholds relating to biological trajectories of cog-
nitive decline had to be adjusted and aligned to the uncertain trajectories of
drug development. The invocation of “not yet” when it comes to both the
development of symptoms and the drug that will eventually treat these
symptoms reinforces the entangled forward-moving trajectory of cognitive
decline and drug development: the race to “beat the biological clock.” In
loosening, denaturalizing, and questioning the logics of the linear progres-
sion of these trajectories, we might think about future potential not just in
terms of “not yet” but as “otherwise” (McTighe and Raschig 2019).
This “not yet” or “otherwise” question relates to the problem–solution
space of Alzheimer’s disease. We have demonstrated that decisions about
readiness were in thrall to a drug that did not yet and may never exist. The
absent drug was a placeholder for the changing needs, goals, and politics of
disease modeling and drug development: the speculative gap between prob-
lems and solutions. This analysis of readiness echoes Brown’s (2000)
description of the “breakthrough motif,” as “intrinsically tied to the twofold
practical orchestration of present problems and future solutions” (p. 89).
But unlike the rhetorical breakthrough motif, readiness enacts and performs
both problems (the pre-Alzheimer’s trajectory) and solutions (drug devel-
opment). In other words, readiness makes both the predisease trajectory and
drug development plausible and workable in an uncertain clinical trial
context.
It is here that we might engage with the “politics of the (im)possible”
(Wilkie, Savransky, and Rosengarten 2017) and consider what else might
be plausible and workable in the bigger picture of Alzheimer’s disease
prevention. By highlighting the genuine openness of the question “ready
for what, and at what time?” we discover an emerging opportunity to
participate in a conversation about what, exactly, holds potential in the field
of Alzheimer’s disease prevention. Our contribution has told the story of the
absent drug that was part of a distributed set of entities that set thresholds
for trial readiness. But what if we considered entities that were not just
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absent but completely invisible or other when it comes to the world of
clinical trials (Law 2004)? This includes the much broader assemblage of
people, things, and tools missing from this particular story, which was
shaped by the core group of scientific actors we described in our introduc-
tion to the EPAD case. Critical historical accounts have highlighted alter-
native paths, which have been neglected or even “thwarted” in the broader
story of Alzheimer’s research (Begley 2019; Lock 2013, 67, 215; Ballenger
2006, 81). Given the contingencies we have pointed out in this paper, the
“right time” for the “right sort of participant” to receive the “right inter-
vention” may look very different if we were to open up the speculative gaps
enough to include other scientific actors, different (un)willing bodies, and
neglected things (Puig de la Bellacasa 2010) within the field of Alzheimer’s
research.
Arriving at such a conclusion gives us pause for thought about the limits
and possibilities of our project, “awkwardly suspended” between observa-
tion and collaboration with clinical research (Balmer et al. 2018). Does this
collaborative project afford the kind of risky suggestions or “outrageous
propositions” (Greco 2017) that speculative social research incites us to
make? Can we participate in the speculative work of adaptive clinical trials,
while maintaining our critical stance on the opacity of the drug development
process? Without claiming to have answered these questions, we treat this
as an opportunity to orient ourselves toward the speculative. As researchers,
we can propose alternative ways of thinking about the politics of time and
timing, brains, and biology as we approach the uncertain future of Alzhei-
mer’s disease research. And as participants in this collaborative work, we
seek to highlight the speculative space and facilitate openings for a broader
constituency of actors to occupy this space. In both cases, we call for a more
generous set of engagements with timings, timescales, and techno-futures
done “otherwise” as we move through the speculative gaps of neurodegen-
erative disease and its prevention.
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Note
1. At the time, the most recent failure in a string of pharmaceutical drug trials, this
one being a compound targeting beta-amyloid tested on participants with pro-
dromal Alzheimer’s disease, much like the trial European Prevention of Alzhei-
mer’s Dementia was gearing up to implement. At the time of writing,
aducanumab has been resurrected as a potentially “successful” drug and is being
submitted by Biogen for Food and Drug Administration approval.
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